Pharma Conversations Podcast

In this episode John Shabushnig, founder of Insight Pharma Consulting explains what visual inspection really means for injectable products, from manual methods to advanced automated systems.
He tackles difficult-to-inspect products, visible particle risk, and common pitfalls in validating automation. John also shows how life-cycle thinking turns inspection data into real process and quality improvements.

Contact us at: pharmaconversationspodcast@gmail.com

This episode is sponsored by Kaye.

In this episode of Pharma Conversations, Maria Ginnelly explains the impact of the EU GMP Annex 1 (section 5.5) on the sterilisation of indirect product-contact parts in sterile manufacturing. She explains why regulators now expect these parts to be treated as critical, why VHP alone is insufficient, and how legacy lines can use QRM, smoke studies, EM/PM, and enhanced gowning to build a defensible contamination control strategy.
Maria also challenges equipment and wrapping vendors to rethink design for Grade A continuity, sharing practical, operator-focused ideas drawn from real-world experience.

Contact us at: pharmaconversationspodcast@gmail.com

This episode is sponsored by Orion GXP Consulting.

In this episode, Charlie Maxwell of Orion GXP Consulting, breaks down what non‑EU pharma and biotech companies need to get right when launching in Europe, from choosing the right HQ location and operating model to deciding between building infrastructure and outsourcing to CDMOs, 3PLs and contract QPs.

Charley explains why Europe is not one homogeneous market, how to avoid “tanking your pricing floor” through poor launch sequencing, and the crucial role of local quality, regulatory and distribution partners in making a European entry successful.

Contact us at: pharmaconversationspodcast@gmail.com

This episode is sponsored by Orion GXP Consulting.

In this episode, Martin Lush of Martin Lush Consulting, breaks down how pharma organizations can safely and effectively adopt AI without sacrificing GMP, quality, or critical thinking. He explains the four types of AI mindsets in pharma, why “AI knows nothing,” and how overreliance and poor foundational knowledge create real risk. Martin also shares practical examples of prompt engineering, governance, and “expert-in-the-loop” approaches that turn AI from a hype-driven threat into a powerful accelerator for quality and productivity.

Contact us at: pharmaconversationspodcast@gmail.com

This episode is sponsored by Orion GXP Consulting.

In this episode Craig Jacobs, Quality Culture Momentum Specialist of Affirm8 Quality Consultancy, unpacks what “quality culture” truly means in life sciences organizations. He explains that real quality shows up when no one is watching on the night shift, in audits, and in everyday process execution. Craig introduces his “4 Ps” model as a way to both understand and measure quality culture over time. He also explores why the quality function often gets blamed when things go wrong, and how clearer accountability across the organization can transform both outcomes and mindset.

Contact us at: pharmaconversationspodcast@gmail.com

This episode is sponsored by STERIS.